INNSIGHT NEWSLETTER
July Edition
 
In these challenging times, keep updated with the latest pharma market news and insights. 

With this July edition of INNsight, we bring you an update on THE IMPACT OF COVID-19 ON FUTURE FORECASTS IN 14 KEY MARKETS, an overview on RET TUMOR THERAPY, as well as the usual LITIGATION UPDATE .

Check IQVIA’s dedicated COVID-19 Resource Center for more IQVIA insights and analyses on COVID-19. 

The INNSight team will be taking a break in August.  We will be back in September, looking forward to sharing more news with you then.
 
Impact of the COVID-19 Pandemic on Global Pharmaceutical Growth
As the impact of the fast-spreading COVID-19 pandemic on pharmaceutical markets worldwide is gradually becoming clearer,  this article explores some of the common dynamics observed in Q1 2020 across 14 key markets and the implications for future growth prospects. Read More
 
 
RET Tumor Therapy: A Milestone Achieved
The approval of selpercatinib and positive data from clinical trials of other RET inhibitors provide further treatment options for patients and opportunities in RET-dependent cancer research, which may include addressing the ability of RET inhibitors to maintain long-term inhibition of tumor cell growth and to tackle potential mechanisms of acquired resistance.
 
Litigation Update
Based on Ark Patent Intelligence data, this article presents an update on the ongoing litigation around Teva’s Invega Sustenna® patent. Read more
 
 
EVENTS WATCH 
 
Listen to our webinar for an analysis on key segments of the off-patent pharmaceutical market including specialty generics, API and value added medicines. We also explore areas of opportunity and market dynamics we might expect over the next few years. Play the
 
The 74th International Pharma Partnering Conference will be attended by top level business development executives from all over the world. Now including flexible partnering euroPLX is the industry's flagship partnering platform for new business opportunities for almost 25 years, providing one of the most advanced interaction hubs that has facilitated about 18,000 business negotiations in 2019 for almost 1,900 companies from 85 countries. Find out more ...
 
This event will address all the opportunities and challenges for the generic, biosimilar and value added medicines sectors within Europe and worldwide, and allow participants to discuss all the main legal and IP issues in the pharmaceutical sector with leading industry executives and experts, counsel and European institution officials.  Find out more ...
 
 
Should you have a colleague who is interested in subscribing to this newsletter, please ask them to register here
 
 
© 2020 IQVIA. All rights reserved.
Contact us at iqvia.com
4820 Emperor Boulevard, Durham, NC 27703, U.S
83 Wooster Heights Road, Danbury, CT 06810, U.S